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Viability of SiRNA as a Clinical Treatment
The future of medicine is heading closer and closer to perfecting 
gene therapy. While research is bringing the option to alter genes 
closer to fruition, there is still a long way until it will be able to 
be implemented. Simpler therapies albeit with their own set of 
problems, seem to be a more realistic option for the foresee-
able future. One in particular that has seen some progress is 
the use of small interfering RNA (siRNA). ”Since its discovery 
by Fire and Mellow in 1998, siRNA has proven to be a powerful 
tool for modulating the expression of almost any gene in various 
species.” (Nechaev, et al, 2013) During Göran Hansson’s speech 
after receiving the noble prize for the discovery of a form of 
RNA silencing, he said, referring to RNAi (more general term for 
siRNA), that it “has added a new dimension to our understanding 
of life and provided new tools for medicine.” (Eggleston, 2009). 
It can have many applications and doesn’t necessarily require 
the alteration of DNA. It allows the DNA to remain in its state 
of disarray however it won’t allow the problematic gene to be 
translated. This allows for control of the gene without having to 
alter the DNA. The applications for this are countless. SiRNA 
can treat many otherwise untreatable diseases ranging from viral 
infections to complex genetic disorders (Endo-Takahashi. et al. 
2012). Although the concept of siRNA is not a new one, there are 
some kinks in how to use it as a treatment. One major setback 
is that although it is now possible to create this aforementioned 
silencing RNA (siRNA), its method of delivery is problematic. The 
siRNA, if delivered indiscriminately, can wreak havoc in cells it 
wasn’t intended for. It can stop crucial growth and functional ele-
ments of important life sustaining cells. It is therefore important 
to deliver these potentially harmful substances only to their in-
tended targets. This is just one of a few issues that can be a major 
hindrance in siRNAs future as a treatment. It is imperative to 
understand how siRNA works before an approach can be found 
to tackle the issues that can arise in using siRNA as a treatment. 
SiRNA silences the expression of specific genes allowing for par-
ticular cell functions to seize. SiRNA begins its life as a double 
stranded RNA molecule (dsRNA). The dsRNA is cleaved into 
shorter siRNAs. This process requires dicer to cleave the large 
dsRNA. The siRNA is incorporated into a protein complex re-
ferred to as RNA inducing silencing complex (RISC). The still 
double stranded siRNA is unwound by the protein complex via 
multiple steps. The now single strand of siRNA leads the RISC to 
the target RNA destroying it (Schwarz, et al, 2014). The destroyed 
mRNA is no longer able to perform the function it was coded for. 
This allows for a cell to continue with its other functions as long 
as the specified protein isn’t crucial for the cells normal function. 
The siRNA does not interact with the genome directly allowing 
for less risk of creating mutant cells. 
Possible Applications of siRNA
SiRNA has been studied largely for its application as a cancer 
suppressor. It has however, many applications beyond that. wheth-
er in its ability to lower circulating cholesterol (Tep, et al, 2012) 
by inhibiting the translation of a specific protein, or as a method 
of controlling HIV-1(Zhou, et al, 2008) as well as possibly reduc-
ing any other potentially harmful protein synthesis. SiRNA can 
have other non-clinical applications as well. Although the same 
basic ideas and methods are used for all potential treatments 
associated with siRNA the broad range of diseases it can poten-
tially treat allows for some unique applications. 
One study on the effects that siRNA can play in treating ovarian 
cancer used a pretty classical method of using siRNA. The surface 
protein cd44 is necessary in activating signal pathways necessary 
for cancer, specifically metastasized, to continue its growth and 
destruction. These pathways instruct the cell to continue tran-
scribing proteins necessary for cell growth, as well as other fac-
tors that allow the cancer cells to live and multiply. The cd44 
protein is also only found to be expressed by metastasized can-
cer cells, thus negating many of the issues associated with siRNA 
delivery that will be discussed later. The study used siRNA as well 
as an anticancer drug to see the combined effects they could 
have on metastasized ovarian cancer. The siRNA was specific to 
mRNA coding for cd44. It was carried out in vitro as well as in 
vivo with similarly successful outcomes; the cancer cells growth 
was slowed dramatically in both tests. Compared to just the use 
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of the cancer drug and other chemotherapies, it was deemed 
more efficient and aggressive. This is a truly great step forward 
in finding a new cure with this rarely used method of treatment. 
(Shah, et al, 2013).
SiRNAs use as a treatment for HIV is also being considered. “HIV-
1 gene expression, during productive and chronic infection, is es-
sentially dependent upon the early regulatory genes tat and rav.” 
(Caputo, et al, 1997) If a method to stop these regulatory genes 
from being expressed can be found it can be used to virtually 
control HIV. Although there have been many improvements in 
controlling and preventing new outbreaks of HIV and the associ-
ated life altering conditions, HIV is still a still prolific disease(Cen-
ters for Disease Control, 2013) .
Working on this premise, researches created a siRNA delivery 
method that is specific to the HIV strain they were interested in 
controlling. The siRNA was manufactured to be specific to the 
genes that coded for tat and rav. In stopping the expression of 
these genes that are crucial for the viability of HIV-1 they were in 
essence stopping the disease. Through methods including quan-
titative real time pcr, they were able to confirm that the genes 
associated with  rav and tat were significantly down regulated 
(Zhou, et al, 2008).  
The extensive range of treatments that can be possible with a 
treatment involving siRNA doesn’t just apply to cases of cancer 
and the HIV virus. It is being evaluated for its potential as a meth-
od of treating conditions involving an increased level of low den-
sity lipoprotein (LDL) cholesterol. “In individuals with 5-year risk 
of major vascular events lower than 10%, each 1 mmol/L reduc-
tion in LDL cholesterol produced an absolute reduction in major 
vascular events of about 11 per 1000 over 5 years” (Cholesterol 
Treatment Trialists’ (CTT) Collaborators. 2012).  A reduction in 
ones LDL levels, specifically in the  amount found in one’s blood 
stream, has proven to reduce the risk of cardiovascular disease 
(Manninen, et al, 1992), and might be a factor in lowering the risk 
of those who have had a stroke previously from having another 
(Sacco, et al, 2006) .
SiRNA can be used indirectly as a way to lower LDL cholesterol 
levels. “ A novel therapeutic approach to lower LDL-c that is cur-
rently in clinical development involves blocking VLDL assembly 
and secretion by inhibiting the microsomal triglyceride transfer 
protein (Mtp)” (Tep, et al, 2012). By using siRNA to inhibit trans-
lation of the gene responsible for Mtp, they were able to reduce 
the levels of LDL cholesterol found in the blood stream. This is 
especially useful for those who don’t react well to the current 
protocol set to reduce LDL levels by prescribing statins.
The broad range of application in a clinical sense for the use of 
siRNAs is apparent from the few studies mentioned. There are 
many other applications that can be utilized, but those mentioned 
here show how broad its ability as a drug can be. Most of these 
studies however, are very theoretical. There are many hurdles 
that must be overcome before being able to use it as a treatment. 
The main hurdles being its delivery to a specific cell and stopping 
a specific protein without affecting others.      
Problems and Their Potential Answers
Delivery of SiRNA to cells has been a major problem for re-
searchers. There are quite a few reasons that it is difficult to 
deliver molecules of siRNA, or more specifically its precursor 
dsRNA, to cells. The first is its really short lifespan. Even if the 
dsRNA won’t degrade before reaching its desired location, the 
trouble of getting it into the cytoplasm of the cell is a hurdle in 
itself. However the biggest issue seems to be how to get these 
crucial siRNAs to a specific cell. Once in the correct cell, prob-
lems may still arise. SiRNA can be finicky at times and down 
regulate proteins that it wasn’t intended for. Basically the siRNA 
has major issues with its specificity on the cellular level as well 
as intercellular. 
“Unmodified, naked siRNAs are relatively unstable in blood 
and serum, as they are rapidly degraded by endo- and exonu-
cleases, meaning that they have short half-lives in vivo.” (Akhtar, 
Benter, 2007). This limits the ability to administer siRNAs in their 
“naked” already modified form. However, chemically modifying 
the siRNAs seems to prevent their untimely degradation. Studies 
were done comparing siRNA in its naked, already modified form, 
to siRNA that was chemically modified either by way of caging, 
nanoparticles, or PEGylation. When this comparison was done 
under conditions that simulated living in the blood stream, the 
siRNA that had been modified showed a significant increase in 
life span. Chemically modifying siRNA seems to be the way to 
allow for the siRNA to survive its journey to the cell. (Shah, et 
al 2013) 
Surviving its journey to the cell is just the first of many hurdles 
for this important new treatment. The next  major stumbling 
block to overcome is how to get it to the cell of choice. Although 
siRNA is selective for specific proteins it can cause havoc in a cell 
it wasn’t intended for. For example, even if a cell doesn’t have the 
specific protein that this siRNA codes for it can cause unwant-
ed mRNA degradation due to off targeting (B. Scaggiante, et al, 
2011), a complication that will be discussed in a more general 
sense in the coming paragraphs. 
Some methods are being studied as ways to allow the delivery 
to be more specific. The use of aptamers has been relatively suc-
cessful in allowing the siRNA to reach specific cells, although it 
has its own unique set of issues (Liu, Gao, 2013). Another method 
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that has been used is connecting the siRNA enclosed in nanopar-
ticles to an existing delivery system. This has shown promising 
results especially when the intended drug is also used (Shah, et al, 
2013). Other methods are showing promising results as well. This 
leads to the next problem of the siRNA being delivered across 
the cell membrane.
SiRNA can be especially difficult to deliver through the cell mem-
brane due to its charge. The cell membrane has an affinity to 
the siRNAs inherent charge causing it to be repelled. There are 
several methods being studied to find the most efficient way of 
allowing molecules of siRNA to penetrate the cell membrane. 
The first is the physical or mechanical method. Using electropo-
ration or ultrasound, for example, to allow for cellular uptake. 
Another method being looked at is the use of chemicals either 
to neutralize the negative charge of siRNA or deliver it through 
other methods. (Zhou, et al, 2008)
With passage of siRNA through the cell now possible, off tar-
geting, the last issue of delivery needs to be resolved. Although 
siRNA is coded uniquely to suppress the desired protein, it isn’t 
always so specific. If a similar protein is also produced in the cell 
that the siRNA is delivered to, it can occasionally down regulate 
that protein as well. A specific protein is one that has a similar 
genetic code even though it can serve a very different and some-
times crucial role in the viability of the specified cell.
A few methods have been used to negate this off target silencing. 
The methods mainly use modifications to the siRNA or dsRNA 
starting material. By modifying the backbone of the strand, im-
proved specificity was able to be reached. Although useful the 
modifications tend to make the siRNA less efficient against the 
target mRNA as well. There is one particularly successful option 
that doesn’t affect the down regulation of the target mRNA as 
much as many of the previous methods tried. This process re-
quires adding a one nucleotide bulge on the antisense strand spe-
cifically at the second positon. The modified siRNA was found to 
be more specific to the intended mRNA producing less mistaken 
down regulation while still properly down regulating its intended 
target. ( Dua, et al, 2011)
With its intended target found, the siRNA can now efficiently 
down regulate it. However, the stable dsRNA that the RISC now 
unwound to use as a mRNA inhibitor, is no longer as stable. 
Due to its less stable state when joining the RISC, “Transfected 
synthetic siRNA works for only a few days in mammalian cells.” 
(Sioud 2004) While multiple treatments may reduce the issue of 
short term effectiveness, a better solution may be available. Using 
retroviral drugs the siRNA can be integrated into the genome 
more specifically as hairpin RNA. This is like the naturally oc-
curring non synthetic siRNA. Using siRNA the cell can regulate 
itself post transcriptionally. By integrating the codons to produce 
siRNA the time frame for siRNA longevity becomes indefinite. 
This is not by it increasing in stability rather it allows for a con-
stant dose without further intervention. (Stewart, et al, 2003) 
Conclusion
The concept of using siRNA as a treatment for humans is one 
that excites and can open many previously unavailable options 
to those suffering many debilitating diseases. It is so promising 
that any stumbling block that has arisen along the way hasn’t 
deterred researchers from their final goal of using siRNA in the 
clinical setting. They have attacked it from every angle and found 
solutions for many problems and ideas for others. The main issue 
of delivery primarily affects reaching specific cells or tissues with 
specificity. There are clinical trials mainly focused on using siRNA 
as a topical treatment. Although this method of treatment has 
been proven successful, by eliminating many of the issues associ-
ated with delivery, it only works on areas that are able to react 
to topical treatments. Topical siRNA treatments have seen much 
progress and continue to pass multiple phases of their testing; 
some have even been approved for clinical use. These treatments 
bypass many of the issues discussed, and show the ability of 
siRNA as a potential treatment for other diseases that need a 
more complex delivery system. 
The extensive opportunities for siRNA use are driving many to 
discover new and improved methods. The way in which siRNA 
has turned from a discovery into clinical trials in a mere fifteen 
years attests to its great potential and likely future as a viable 
treatment. There are many areas that are still unclear especially 
regarding the methods in which siRNA works. With more discov-
ery and new technology the methods of delivery and treatments 
will likely improve and start the important work siRNA was in-
tended for.
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